Senior Director, Health Economics and Outcome Research/Real World Evidence at Amylyx Pharmaceuticals

Cambridge, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

Candidates must possess a Master's Degree (MS, MPH, PharmD, PhD) in a relevant discipline such as health economics, medicine, pharmacy, public health, or epidemiology. A minimum of 10 years of experience in the healthcare or pharmaceutical industry is required, with at least 7 of those years specifically in Health Economics and Outcomes Research (HEOR).

Responsibilities

The Senior Director, HEOR/RWE will lead the development of integrated HEOR and evidence generation strategies and tactical plans for therapeutic programs. This includes conducting evidence gap analyses, designing and executing real-world evidence studies, and overseeing the development of publications and presentations. The role involves supporting global market access strategies, collaborating with cross-functional teams on evidence packages for payers, and managing HEOR budgets and external research partners. Additionally, the position requires monitoring and interpreting U.S. policy changes and translating their implications into actionable HEOR strategies.

Skills

Health Economics and Outcomes Research (HEOR)

Real World Evidence (RWE)

Evidence Generation Strategies

Value Proposition Development

Market Access

Strategic Planning

Data Generation

Communication Planning

Amylyx Pharmaceuticals

Develops treatments for neurodegenerative diseases

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials to assess its effectiveness. The CENTAUR ALS trial showed promising results for ALS patients, using a randomized, double-blind, placebo-controlled design to ensure reliable outcomes. They are also conducting the PEGASUS trial to evaluate AMX0035's safety and effectiveness in Alzheimer's patients. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes and enhance the quality of life for individuals suffering from neurodegenerative conditions.

Cambridge, MassachusettsHeadquarters

2013Year Founded

$166.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Remote Work Options

Risks

Relyvrio's Phase III failure raises concerns about ALS treatment efficacy.

Low stock offering price suggests potential financial instability.

New CCO may disrupt commercialization strategies if not aligned with goals.

Differentiation

Amylyx focuses on neurodegenerative diseases like ALS and Alzheimer's.

AMX0035 is a promising drug for ALS and Alzheimer's treatment.

Amylyx engages in community awareness campaigns for neurodegenerative diseases.

Upsides

Positive Phase II results for AMX0035 in ALS boost its potential.

Partnership with Gubra accelerates drug development for neurodegenerative diseases.

Regulatory support for rare diseases aids Amylyx's Wolfram syndrome efforts.

Land your dream remote job 3x faster with AI

Try Jobo Free